摘要
目前乳腺癌是全球女性最常见的恶性肿瘤。70%~80%的乳腺癌为激素受体(hormone receptor,HR)阳性,针对这一类型乳腺癌的主要治疗手段为内分泌治疗。其中约30%的患者在经过一段时间的内分泌治疗后发生复发转移,产生内分泌耐药,最终发展为晚期乳腺癌。针对内分泌耐药的机制已有少数有效的靶向药物获批应用于临床治疗,然而对于这些靶向药物,部分患者也会产生耐药或者因严重不良反应而停药,导致病情进展。乳腺癌内分泌耐药是多通路、多靶点共同作用的结果,仅仅抑制单个靶点,不可避免地会再次发生耐药,而多个靶向药物联合治疗内分泌耐药尚处于临床试验阶段。而中医药具有多成分、多靶点、多通路、低毒、增效、经济等独特优势,在乳腺癌不同阶段的治疗中发挥着日渐凸显的重要作用。本文将对中医药治疗乳腺癌内分泌耐药的研究现状进行综述,以期为临床克服乳腺癌内分泌治疗耐药问题提供新的思路。
Breast cancer is the most common malignancy worldwide in women.Seventy to eighty percent of breast cancer are hormone-receptor(HR)positive,and endocrine therapy is the main strategy for this type of breast cancer.About 30%of these patients develop relapse and metastasis after a period of endocrine therapy,and also have endocrine resistance,which eventually develop advanced breast cancer.According to the mechanism of endocrine resistance,a few effective targeted drugs have been approved for clinical treatment.However,for these targeted drugs,some patients may develop drug resistance or stop taking the drugs due to serious adverse reactions,which leads to disease progression.Endocrine resistance in breast cancer is the result of the combined action of multiple pathways and multiple targets.If only a single target is inhibited,drug resistance will inevitably occur again.But yet the combined treatment of multiple targeted drugs for endocrine resistance is still in the stage of clinical trials.Traditional Chinese medicine,with its unique advantages of multi-component,multi-target,multi-pathway,low toxicity,synergism and economy,plays an increasingly prominent role in the treatment of breast cancer at different stages.This paper reviewed the current research status of traditional Chinese medicine for the treatment of endocrine resistance in breast cancer,in order to provide new ideas for clinical overcoming the problem of endocrine resistance in breast cancer.
作者
王鲁娇
李育林
司文涛
侯爱画
WANG Lu-jiao;LI Yu-lin;SI Wen-tao;HOU Ai-hua(Shandong University of Traditional Chinese Medicine,Jinan 250355 Shandong,China;Yantai Hospital of Traditional Chinese Medicine,Yantai 264013 Shandong,China)
出处
《中医肿瘤学杂志》
2023年第5期84-94,共11页
Journal of Oncology in Chinese Medicine
基金
山东省中医药科技项目(编号:2021M091)
齐鲁中医药优势专科集群建设项目(肿瘤科)。
关键词
中医药
乳腺癌
内分泌耐药
作用机制
研究进展
traditional Chinese medicine
breast cancer
endocrine resistance
therapeutic mechanism
research progress
